## Amendments to the Specification

Please amend the paragraph at page 1, lines 16-19, so as to read:

This is a Continuation Application based upon U.S. Patent Application Serial No. 09/866,514 filed May 25, 2001 (now U.S. Pat. No. 6,652,862), which is a Continuation of U.S. Patent Application Serial No. 09/309,217 filed May 10, 1999 (now U.S. Pat. No. 6,287,811), which is a Continuation of U.S. Patent Application Serial No. 08/361,299 filed January 23, 1995 (now U.S. Pat. No. 5,948,408), which is a Continuation of U.S. Patent Application Serial No. 08/007,837 filed January 22, 1993 (now U.S. Pat. No. 5,641,874), which is a Continuation of U.S. Patent Application Serial No. 07/805,031 filed December 11, 1991 (now U.S. Pat. No. 5,198,541). which is a Divisional of U.S. Patent Application Serial No. 07/762,730 filed September 17, 1991 (now abandoned), which is a File-Wrapper Continuation of U.S. Patent Application Serial No. 07/228,035 filed August 5, 1988 (now abandoned), which is a Continuation-In-Part of U.S. Patent Application Serial No. 07/084,335 filed August 11, 1987 (now abandoned).

Please amend the paragraph at page 5, lines 19-21, so as to read:

FIG. 2 is a graph FIGS. 2a and 2b are graphs showing the chromatographic behavior of the human BPI holoprotein (a) and human 25 kDa BPI fragment of the present invention (b) on reverse phase HPLC.

Please amend the paragraph at page 5, lines 22-27, so as to read:

FIG. 3 is FIGS. 3A-3D are a series of graphs comparing the biological activities of the 25 kDa human BPI fragment of the present invention and the holoprotein toward E. coli J5. (A) bactericidal activity;

Application No. 10/716,389 Amendment dated September 26, 2005 Response to Office Action of March 25, 2005

(B) effect on bacterial protein synthesis; (C) permeability increasing activity; and (D) phospholipase activation.

Please amend the paragraph at page 5, lines 31-34, so as to read:

FIG. 5 (including FIGS. 5A-5D), bottom line, shows the sequence of the cDNA encoding human BPI whereas printed above is the corresponding amino acid sequence. The two potential glycosylation sites are overlined.